Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG

Cheng Hsun Ho, Hung-Wen Tsai, Chen Yeh Lee, Li Juan Huang, Rong Nan Chien, I-Chin Wu, Yen-Cheng Chiu, Wen Chun Liu, Pin-Nan Cheng, Ting-Tsung Chang, Shu-Hui Chen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30% was an independent factor that links to virological response (HR 3.071, 95% CI 1.835-5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95% CI 1.011-4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.

Original languageEnglish
Article number1957
JournalScientific reports
Volume7
Issue number1
DOIs
Publication statusPublished - 2017 Dec 1

Fingerprint

Hepatitis B e Antigens
Immunoglobulin G
Hepatitis B virus
Serum
Therapeutics
Liver
Chronic Hepatitis B
Virus Diseases
Glycosylation
Drug Resistance
Antiviral Agents
Mass Spectrometry
Regression Analysis
Inflammation
DNA

All Science Journal Classification (ASJC) codes

  • General

Cite this

@article{481a4b7e5f2e459f8c9fc81bccaed667,
title = "Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG",
abstract = "Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30{\%} was an independent factor that links to virological response (HR 3.071, 95{\%} CI 1.835-5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95{\%} CI 1.011-4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.",
author = "Ho, {Cheng Hsun} and Hung-Wen Tsai and Lee, {Chen Yeh} and Huang, {Li Juan} and Chien, {Rong Nan} and I-Chin Wu and Yen-Cheng Chiu and Liu, {Wen Chun} and Pin-Nan Cheng and Ting-Tsung Chang and Shu-Hui Chen",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-02158-5",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG. / Ho, Cheng Hsun; Tsai, Hung-Wen; Lee, Chen Yeh; Huang, Li Juan; Chien, Rong Nan; Wu, I-Chin; Chiu, Yen-Cheng; Liu, Wen Chun; Cheng, Pin-Nan; Chang, Ting-Tsung; Chen, Shu-Hui.

In: Scientific reports, Vol. 7, No. 1, 1957, 01.12.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG

AU - Ho, Cheng Hsun

AU - Tsai, Hung-Wen

AU - Lee, Chen Yeh

AU - Huang, Li Juan

AU - Chien, Rong Nan

AU - Wu, I-Chin

AU - Chiu, Yen-Cheng

AU - Liu, Wen Chun

AU - Cheng, Pin-Nan

AU - Chang, Ting-Tsung

AU - Chen, Shu-Hui

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30% was an independent factor that links to virological response (HR 3.071, 95% CI 1.835-5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95% CI 1.011-4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.

AB - Aberrant IgG glycosylation is a feature of hepatitis B virus (HBV) infection but its effect on a long-term efficacy of antiviral therapy has never been addressed. After a screening of 1,085 patients, 132 eligible HBV e antigen (HBeAg)-positive and 101 HBeAg-negative patients with anti-HBV nucleos(t)ide analogue monotherapy were enrolled with on-treatment follow-ups for at least one year. IgG1 N-glycome was profiled using mass spectrometry and evaluated for its relevance in treatment responses. The results indicated that a high level of serum fucosyl-agalactosyl IgG1 (IgG1-G0F) at baseline was associated with the severity of liver inflammation and damage but advanced treatment responses, including HBV DNA loss, HBeAg seroconversion, a reduced drug resistance rate, and a liver histological improvement at year 1, thereby improving the long-term treatment efficacy and the probability of treatment discontinuation in HBeAg-positive patients. Stepwise Cox regression analyses revealed that baseline IgG1-G0F >30% was an independent factor that links to virological response (HR 3.071, 95% CI 1.835-5.141, P < 0.001) or HBeAg seroconversion (HR 2.034, 95% CI 1.011-4.093, P = 0.046). Furthermore, a high IgG1-G0F level at the treatment endpoint was associated with an off-treatment sustained virological response. In conclusion, IgG1-G0F favors the medication outcome for HBeAg-positive chronic hepatitis B.

UR - http://www.scopus.com/inward/record.url?scp=85019417651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019417651&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-02158-5

DO - 10.1038/s41598-017-02158-5

M3 - Article

C2 - 28512353

AN - SCOPUS:85019417651

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1957

ER -